Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gerber

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesHans-Peter Gerber, Xiumin Wu, Lanlan Yu, et al.
Bioconjugate Chemistry|July 15, 2016
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) PayloadsSujiet Puthenveetil, Frank Loganzo, Haiyin He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesHans-Peter Gerber, Xiumin Wu, Lanlan Yu, et al.
Bioconjugate Chemistry|July 15, 2016
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) PayloadsSujiet Puthenveetil, Frank Loganzo, Haiyin He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, et al.
Cell Reports. Medicine|June 7, 2021
NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cellsKenneth G Geles, Yijie Gao, Andreas Giannakou, et al.
Molecular Cancer Therapeutics|July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint BlockadeAndrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Molecular Cancer Therapeutics|August 5, 2020
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung CancersEdmund I Graziani, Matthew Sung, Dangshe Ma, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Pageof 11